BioSpace

Milestone Sanfilippo nod helps Ultragenyx regroup after tough Angelman defeat

The recent FDA approval of Fayuvi for a rare, childhood neurodegenerative disease was “particularly special” for Ultragenyx CEO Emil Kakkis. It could also, along with an August nod for another gene therapy, help offset recent challenges brought on by two asset failures.

作者 BioSpace

1 分钟阅读
Milestone Sanfilippo nod helps Ultragenyx regroup after tough Angelman defeat
Milestone Sanfilippo nod helps Ultragenyx regroup after tough Angelman defeat

有活动行业的新闻要分享吗?

提交新闻稿或信息,触达数千名活动行业专业人士。

联系我们→

更多Health Tech相关内容

相关洞察